Ligands secreted by START, such as GAS6 and ICAM, lead to a protumoral phenotype acquisition (M2 phenotype) in the IMs, while CXCL2 and GRN, secreted by IMs, trigger tumor growth in START (Fig. 4N). The gene discussed is CXCL2; the disease is neoplasm.